Clinical trials: Neutrophils
ANCA Associated Vasculitis (AAV)
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
- Trial name
- NCT06868290
- Testing
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Where
- 39 sites in United States, Brazil and 6 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Bronchiectasis, Lung Disease
Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis
The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.
- Conditions
- Bronchiectasis, Lung Disease, Respiratory Diseases
- Trial name
- STRATUS (NCT01255592)
- Testing
- AZD5069
- Where
- 15 sites in Czechia, Poland and 1 more
- Volunteers
- 83 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers
Study to assess effect of Fluticasone Propionate on acute lung inflammation following inhaled lipopolysaccharide (LPS) challenge. Study will be conducted in healthy volunteers.
- Trial name
- NCT01364519
- Testing
- Fluticasone Propionate
- Where
- 2 sites in United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- CIRRUS (NCT01233232)
- Testing
- AZD5069 50mg, AZD5069 80mg
- Where
- 8 sites in Bulgaria, Germany and 2 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF
"This is a randomised, double-blind, placebo-controlled multi-centre study to investigate safety and tolerability and to provide pharmacokinetic and pharmacodynamics information of orally inhaled multiple doses (80 mg, 160 mg or…
- Trial name
- NCT03748199
- Testing
- POL6014
- Where
- 4 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Santhera Pharmaceuticals
Neoplasm Malignant
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
Primary Objective: To assess the safety, tolerability and plasma pharmacokinetics (PK) of SAR245408 given once daily as a tablet formulation of polymorph E in subjects with solid tumors or lymphoma.
- Trial name
- NCT01943838
- Testing
- SAR245408
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Sanofi
LPS Challenge, Neutrophils
Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge
Study to investigate the effect of a single dose of AZD7624 on inflammation caused by an endotoxin challenge.
- Trial name
- NCT01937338
- Testing
- AZD7624
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Granulomatosis With Polyangiitis
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
This Phase IIa international multicenter, open-label, uncontrolled study will evaluate the safety and pharmacokinetics of rituximab (MabThera/Rituxan) in pediatric participants with severe granulomatosis with polyangiitis (GPA)…
- Trial name
- NCT01750697
- Testing
- Rituximab
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
The primary objective of this study is to perform mass balance following a single oral dose of [14C]CCX168 in healthy adult male participants.
- Trial name
- NCT06004960
- Testing
- [14C]CCX168
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Amgen
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as…
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- ROSY-F (NCT07444567)
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Fever, Neutropenia
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in patients with fever and neutropenia
- Conditions
- Fever, Neutropenia, Gram-positive Bacterial Infections, Pseudomonas Infection
- Trial name
- NCT00529282
- Testing
- Ceftobiprole Medocaril, Cefepime with or without vancomycin
- Volunteers
- 2 people
- Sponsor
- Basilea Pharmaceutica
Pulmonary Disease, Chronic Obstructive
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
The inflammation associated with COPD is characterized by a prominent infiltration of neutrophils in lung tissue and airways. The CXC chemokine receptor type 2 (CXCR2) plays a pivotal role in neutrophil recruitment to the lungs…
- Trial name
- NCT03250689
- Testing
- Danirixin, Rescue medication, Inhaled COPD maintenance medication
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
ANCA-associated Vasculitis
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
The aim of this trial is to test the safety and efficacy of two dose regimens of the complement C5a receptor CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
- Trial name
- NCT02222155
- Testing
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
- Where
- 43 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Amgen
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.
- Trial name
- BIANCA-SC (NCT01598857)
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease
This is an exploratory study to further develop an imaging platform for the assessment of whole lung neutrophil retention. The primary objective of the study is to quantify and compare neutrophil retention in the lungs of…
- Trial name
- NCT02551614
- Testing
- Lipopolysaccharide challenge, Saline challenge, Labelled neutrophils and Imaging assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Healthy Volunteers
Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers
This will be a randomized, single dose, open-label, three-treatment period crossover study in healthy participants to determine whether 2 test lots of 10-mg capsules that vary by the level of lenvatinib Type-C crystal are…
- Trial name
- NCT02723630
- Testing
- Lenvatinib 10 mg
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.